Watch CBSN Live

Wilco's Bennett Killed by Fentanyl; Is It Time to Tighten Rules on Patch Drugs?

An Illinois coroner said Wilco songwriter Jay Bennett died of an accidental overdose from a fentanyl painkiller patch. The death should give the pharmaceutical industry pause to ask whether patch delivery systems should be subject to higher standards before being approved.

Fentanyl patches, marketed as Duragesic by Johnson & Johnson's PriCara unit and also available as generics, are for opioid-tolerant patients who need round-the-clock pain relief. Fentanyl is also highly addictive, about 100 times more potent than heroin. Bennett was using the patch to dull pain from his hip, which he injured performing, according to the Chicago Tribune. He did not die from recreational drug use, the coroner noted. (It is not known whether a J&J or generic patch killed him.)

The problem with patches is that they use a structurally inappropriate organ to deliver medicine -- the skin. If a drug can be persuaded to pass though the skin, it enters the blood at a constant, unmediated rate. (By contrast, a drug swallowed as a pill will be digested, and the dose in the blood will rise and then fall before the next pill is taken, giving the body a "rest" between metabolism tasks.) A constant rate of dose delivery sounds great on paper -- doctors can be sure of more accurately delivering the correct amount of medicine. But because transdermal patches don't give patients' bodies a rest, patients may end up getting too much drug -- as Bennett did.

The history of skin-patch transdermal delivery systems is an unfortunate one. Whether it's contraception, painkillers or ADHD drugs, they are plagued with problems. Here's a list:

View CBS News In